![conference banner](/images/conference-banner.jpeg)
Abstract
Pulmonary oedema (PO) can emerge from mechanical disorders in pulmonary circulation leading to elevated fluid filtration in the lung, or from increased vascular permeability due to inflammatory or toxic injury of the alveolarcapillary barrier. A number of these disorders causing PO is associated with increased catecholamine (CA) levels in plasma and lung tissue and/or increased sympathetic activation such as neurogenic PO, high-altitude PO or PO in patients with phaeochromocytoma. Experimental CA stimulation in animals induced PO after less than one hour of infusion. Both α- and β-adrenergic mechanisms are involved in the pathogenesis but also in the resolution of PO. CAs increase pulmonary capillary pressure and thus, enhance fluid filtration into the pulmonary interstitium. Additionally, by activation of proinflammatory cytokines, they induce pulmonary inflammation that may lead to capillary leak. Finally, they play an important role in the regulation of alveolar fluid clearance. The present paper considers the pathways by which CAs contribute to the development of PO of various origin.
Keywords: nitric oxide (NO), high altitude pulmonary oedema (HAPE), capillary permeability, Acute respiratory distress syndrome (ARDS), right ventricular systolic pressure (RVSP), Inflammation, Cytokines
Cardiovascular & Hematological Disorders-Drug Targets
Title: The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Volume: 7 Issue: 1
Author(s): Beate Rassler
Affiliation:
Keywords: nitric oxide (NO), high altitude pulmonary oedema (HAPE), capillary permeability, Acute respiratory distress syndrome (ARDS), right ventricular systolic pressure (RVSP), Inflammation, Cytokines
Abstract: Pulmonary oedema (PO) can emerge from mechanical disorders in pulmonary circulation leading to elevated fluid filtration in the lung, or from increased vascular permeability due to inflammatory or toxic injury of the alveolarcapillary barrier. A number of these disorders causing PO is associated with increased catecholamine (CA) levels in plasma and lung tissue and/or increased sympathetic activation such as neurogenic PO, high-altitude PO or PO in patients with phaeochromocytoma. Experimental CA stimulation in animals induced PO after less than one hour of infusion. Both α- and β-adrenergic mechanisms are involved in the pathogenesis but also in the resolution of PO. CAs increase pulmonary capillary pressure and thus, enhance fluid filtration into the pulmonary interstitium. Additionally, by activation of proinflammatory cytokines, they induce pulmonary inflammation that may lead to capillary leak. Finally, they play an important role in the regulation of alveolar fluid clearance. The present paper considers the pathways by which CAs contribute to the development of PO of various origin.
Export Options
About this article
Cite this article as:
Rassler Beate, The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187152907780059038
DOI https://dx.doi.org/10.2174/187152907780059038 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Current Alzheimer Research Anderson-Fabry Disease in Children
Current Pharmaceutical Design Preliminary Structural Studies of the Hydrophobic Ribosomal P0 Protein from Trypanosoma cruzi, A Part of the P0/P1/P2 Complex
Protein & Peptide Letters Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs
Current Drug Targets Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Platelet Resistance to Antiplatelet Drugs
Recent Patents on Cardiovascular Drug Discovery Tachykinins and Neuropsychiatric Disorders
Current Drug Targets Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology On the Interaction Between Human IQGAP1 and Actin
Protein & Peptide Letters Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Peptide Based Therapy for Neurological Disorders
Current Protein & Peptide Science A Yeast Extract High in Bioactive Peptides has a Blood-Pressure Lowering Effect in Hypertensive Model
Current Medicinal Chemistry Use of Diuretics in Women for Management of Hypertension
Current Hypertension Reviews Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews Effects of Ganoderma Lucidum on Contractile Dysfunction of the Rabbit Urinary Bladder using an In-Vitro Model of Ischemia/Reperfusion
The Natural Products Journal Comparison of Oxidative Stress and Inflammation Induced by Different Intravenous Iron Sucrose Similar Preparations in a Rat Model
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Mitochondria in Cardiovascular Diseases
Current Pharmaceutical Design Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design